MarketPulse

regulatory submissions

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Inmune Bio Inc.

INmune Bio Slashes Losses 44% in Q1 2026 While Advancing Alzheimer's Pipeline

INmune Bio reported Q1 2026 net loss of $5.4M, down from $9.7M year-ago. Company advancing XPro for Alzheimer's with $21.4M cash on hand.
INMBclinical trialsQ1 2026 earnings
GlobeNewswire Inc.GlobeNewswire Inc.··Accumulus Technologies

Accumulus Launches Veeva RIM Integration, Streamlining Regulatory Submissions for Life Sciences

Accumulus launches Veeva RIM integration enabling real-time regulatory submissions. Amgen early adopter reports significant time savings and operational improvements.
AMGNVEEVdigital transformationlife sciences